ProCE Banner Activity

An Expert Roundtable Exploring Recent Data in Ovarian Cancer and its Impact on Patient Care

Explore recent data from key clinical trials followed by expert discussion with distinguished experts Nicolette Colombo, MD, Ignace Vergote, MD, PhD and Isabelle Ray Coquard MD, PhD.

Released: December 13, 2019

Expiration: December 11, 2020

No longer available for credit.

Share

Faculty

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Ignace Vergote

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Learning Objectives

  • Assess the improvement in risk of progression and time to next treatment from the addition of PARP inhibitors in front-line treatment
  • Describe the recent clinical trial results on the use of PARP inhibitors for the front-line treatment of ovarian cancer
  • Discuss patient and tumor characteristics that identify candidates for treatment with frontline PARP inhibitors and specific regimens

Faculty Disclosure

Primary Author

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Isabelle Ray Coquard, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca, Clovis, Genmab PharmaMar, Roche, and Tesaro, and fees for non-CME/CE services from AstraZeneca, Clovis, PharmaMar, and Tesaro.

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Ignace Vergote, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Biocad, Immunogen, Merck, MSD, PharmaMar, Roche, Sotio, and Tesaro/GSK, and funds for research support from Amgen, AstraZeneca, and Roche.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, Senior Director, Global Medical Education, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, Senior Director, Educational Strategy, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, Associate Director, Scientific Services, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, Scientific Director, Global Medical Education, has no relevant conflicts of interest to report.